Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 7/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.37 |
| ▸ | CDK4 | P11802 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
| ▸ | CDK7 | P50613 | 2/20 | 0.37 |
| ▸ | CDK9 | P50750 | 2/20 | 0.37 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 10/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21414426 | 0.91 | TLR9 (0.38) | TLR9TLR8TLR7CDK1CDK4 | |
| SCHEMBL20203607 | 0.89 | KDR (0.39) | CDK1CDK4CDK2CDK7CDK9 | |
| SCHEMBL20203609 | 0.87 | CDK4 (0.34) | TLR9TLR8TLR7CDK1CDK4 | |
| SCHEMBL20203642 | 0.85 | CDK4 (0.47) | CDK1CDK4CDK2CDK7CDK9 | |
| SCHEMBL23733468 | 0.84 | NPC1 (0.42) | CDK1CDK4CDK2CDK7CDK9 | |
| SCHEMBL20203582 | 0.84 | KDR (0.40) | CDK1CDK4CDK2CDK7CDK9 | |
| SCHEMBL20203603 | 0.83 | CDK1 (0.46) | TLR9TLR8TLR7CDK1CDK4 | |
| SCHEMBL20203586 | 0.81 | ALDH1A1 (0.37) | TLR9TLR8TLR7CDK1CDK4 | |
| SCHEMBL20203591 | 0.81 | GABRG2 (0.36) | CDK1CDK4CDK2CDK7CDK9 | |
| SCHEMBL20203605 | 0.80 | KDM4E (0.43) | TLR9TLR8TLR7CDK1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | TEIJIN PHARMA LIMITED (JP) | 2021-08-10 | — | — | US | disclosed |
| EP-3546458-B1 | ((PYRIDIN-2-YL)-AMINO)PYRIDO[3,4-D]PYRIMIDINE AND ((PYRIDAZIN-3-YL)-AMINO)PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES AS CDK4/6 INHIBITORS FOR TREATING E.G. RHEUMATOID ARTHRITIS, ARTERIOSCLEROSIS, PULMONARY FIBROSIS, CEREBRAL INFARCTION OR CANCER | TEIJIN PHARMA LTD (JP) | 2021-01-06 | — | — | EP | disclosed |
| EP-3546458-A1 | PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2019-10-02 | — | — | EP | disclosed |
| WO-2018097297-A1 | PYRIDO[3, 4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 帝人ファーマ株式会社 | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084814-B2 | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof | CDK4, CDK6, CDK16 | TLR9 1479/4885TLR8 2089/4885TLR7 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.